Pfizer and BioNTech secures clearance for their XFG-targeted COVID-19 vaccine across EU member states

Pfizer and BioNTech have recently confirmed that regulatory clearance has been granted by the European Commission for their 2026-2027 COVID-19 vaccine, engineered to address the XFG variant, covering active protection against SARS-CoV-2-induced COVID-19 in people from six months of age upward. The reformulation responds to guidance from the European Medicines Agency’s Emergency Task Force, which concluded that aligning vaccines with the XFG variant of the JN.1 lineage would offer the greatest protective benefit heading into the 2026-2027 season.

Authorisation extends across every one of the 27 EU member states and covers Iceland, Liechtenstein, and Norway. Manufacturing of the monovalent XFG-targeted vaccine got underway at risk ahead of formal clearance, ensuring stockpiles are in place before the respiratory illness season brings a surge in vaccination demand. Supplies reaching EU member states and Norway will flow either through the European Commission procurement arrangement or via each country’s own governmental policy.

The path to this authorisation ran through a Committee for Medicinal Products for Human Use recommendation on 23 July 2026, anchored in an extensive body of evidence assembled by both companies. The submission combined clinical, non-clinical, and real-world findings attesting to the safety and effectiveness of the Pfizer-BioNTech vaccine platform, with manufacturing, quality, and laboratory data confirming the XFG-targeted formulation’s capacity to mount strong immune responses against a broad sweep of circulating SARS-CoV-2 strains, including XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1, and additional lineages active in the current environment.
Regulatory packages for the reformulated vaccine have been lodged with health authorities in countries across the globe, as both companies maintain close surveillance of shifting COVID-19 transmission patterns to position themselves to respond to evolving public health demands worldwide.

The vaccine at the heart of this authorisation was conceived and developed through a joint effort between Pfizer and BioNTech, drawing on BioNTech’s proprietary mRNA platform. BioNTech serves as the holder of the marketing authorisation for the Pfizer-BioNTech COVID-19 vaccine and subsequent adapted versions in the US, the EU, the UK, and several further jurisdictions, alongside emergency use authorisations or their equivalents in other territories.

---

---

Related Topics and Keywords

BioNTech, covid, Covid-19, COVID-19 vaccine, European Commission, Pfizer, XFG-targeted COVID-19